美国药品关税对哪些企业潜在影响更大？这些指标透露关键信息

Core Viewpoint - The announcement of potential tariffs on imported pharmaceuticals by the U.S. government is expected to impact the pharmaceutical industry, but many companies believe it will not significantly affect their performance in the near term [1][2]. Group 1: Tariff Impact and Company Responses - President Trump announced that the U.S. will initially impose "small tariffs" on imported drugs, potentially increasing to 250% over 18 months to boost domestic production [1]. - Companies like Pfizer and Amgen have indicated that they have sufficient production capacity in the U.S. to mitigate the impact of tariffs [2]. - Biogen expects that Trump's tariff policy will not significantly affect its profits this year, as a large portion of its revenue comes from domestic manufacturing [2]. - AbbVie stated that it will not be significantly impacted by tariffs due to its extensive U.S. manufacturing base and plans to continue investing in the U.S. [3]. Group 2: Manufacturing and Production Capabilities - Key indicators such as the number and geographical distribution of manufacturing plants, production facility utilization, and the origin of active pharmaceutical ingredients will determine a company's ability to withstand tariff risks [3][4]. - Companies like AbbVie, AstraZeneca, Eli Lilly, Merck, and Pfizer have the largest manufacturing networks in the U.S., each with over 10 major manufacturing plants [3]. - AbbVie, Eli Lilly, and BMS are among the few companies with more major plants in the U.S. than overseas, which positions them favorably against tariff impacts [4]. Group 3: Market Reactions and Financial Projections - The market reacted moderately to the tariff news, with Pfizer's stock rising over 5%, while others like Eli Lilly and Johnson & Johnson saw slight declines [1]. - Amgen raised its 2025 revenue forecast, reflecting the anticipated impact of tariffs, while not accounting for any future tax actions [2]. - Sanofi believes the impact of tariffs is manageable and has raised its sales growth forecast for the year [5].